Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

ID: 1457577
recent pressrelease next pressrelease

(businesspress24) - LOS ANGELES, CA -- (Marketwired) -- 09/12/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Palace Hotel in New York City.

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, 455 Madison Avenue at 50th Street, NYC.
Date: September 12, 2016
Time: 4:40PM Eastern
Location: Kennedy II, 4th Floor

Robert Brooke, CEO of Vitality Biopharma, will deliver the Company''s corporate presentation and discuss recent business highlights. In addition to the presentation, Mr. Brooke will also be available for one-on-one meetings.

To find out more about Vitality Biopharma and the important work it performs, please visit .

The Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, will be held on from September 8 to September 10, 2015, at the St. Regis Hotel in New York. More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees. The event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities.

(OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: . Follow us on , and .

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

1-530-231-7800



More information:
http:// http://www.scor.com/en.html http://www.bavarian-nordic.com http://www.atosorigin.com/corporate/default.htm http://www.igmfinancial.com/english/ http://www.vitality.bio/



Keywords (optional):

stvf, vitality-biopharma, cannabinoids, neurological, inflammatory, disorders, rodman, brooke, lotte,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: Marketwired
print pressrelease  send to a friend  

Date: 09/12/2016 - 11:49
Language: English
News-ID 1457577
Character count: 4633
Kontakt-Informationen:
Firma: Vitality Biopharma, Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: LOS ANGELES, CA
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 253

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 58


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.

Categories:


[ more PressReleases ][ RSS-Feed ]